Search

Displaying results 1561 - 1570 of 8517 in total
  1. Drug

    Serdexmethylphenidate

    go.drugbank.com/drugs/DB16629
    Approved

    [L32298, L32323] Serdexmethylphenidate was granted FDA approval on March 2, 2021, and is currently marketed as a combination capsule with [dexmethylphenidate] under the trademark AZSTARYS™ by KemPharm … such as [methylphenidate] and [amphetamine] that increase extracellular dopamine and norepinephrine levels.

  2. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    [A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842] … [L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.

  3. Drug

    Anileridine

    go.drugbank.com/drugs/DB00913
    ApprovedIllicitWithdrawn

    Anileridine is a synthetic opioid and strong analgesic medication. It is a narcotic pain reliever used to treat moderate to severe pain. Narcotic analgesics act in the central nervous system (CNS) to relieve pain. Some of their side effe...

  4. Drug

    Alfuzosin

    go.drugbank.com/drugs/DB00346
    Approved

    The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. … [L31593] It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.[L9251]

  5. Drug

    Sodium hydroxide

    go.drugbank.com/drugs/DB11151
    Approved

    Interestingly, sodium hydroxide has been studied for its use in the treatment of prion disease (as occurs in mad cow disease and kuru). … According to the the FDA, sodium hydroxide is considered a direct food recognized as safe, where it serves as a pH control agent and follows good manufacturing guidelines [L1967].

  6. Drug

    Omidenepag isopropyl

    go.drugbank.com/drugs/DB15071
    Approved

    The use of an EP2 receptor agonist such as omidenepag represents an alternative in these scenarios. Omidenepag IOP-lowering effect is comparable to the one observed with [latanoprost]. … [A253253] In 2018, omidenepag isopropyl was approved in Japan for the treatment of glaucoma and ocular hypertension.[A253268] In September 2022, the FDA approved the use of omidenepag isopropyl.

  7. Drug

    Eslicarbazepine acetate

    go.drugbank.com/drugs/DB09119
    ApprovedInvestigational

    Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled … Eslicarbazepine acetate is marketed as Aptiom in North America and Zebinix or Exalief in Europe. It is available in 200, 400, 600, or 800mg tablets that are taken once daily, with or without food.

  8. Drug

    Afatinib

    go.drugbank.com/drugs/DB08916
    ApprovedInvestigational

    Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. … For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected

  9. Drug

    Phenylbutyric acid

    go.drugbank.com/drugs/DB06819
    ApprovedInvestigational

    It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical chaperone.

  10. Drug

    Fexofenadine

    go.drugbank.com/drugs/DB00950
    ApprovedInvestigational

    [diphenhydramine], which readily bind to off-targets that contribute to side effects such as sedation. … for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier[L10779] - this is in contrast to previous first-generation antihistamines, such as